PT3101131T - Anticorpo antitranstirretina humanizado - Google Patents
Anticorpo antitranstirretina humanizadoInfo
- Publication number
- PT3101131T PT3101131T PT157432303T PT15743230T PT3101131T PT 3101131 T PT3101131 T PT 3101131T PT 157432303 T PT157432303 T PT 157432303T PT 15743230 T PT15743230 T PT 15743230T PT 3101131 T PT3101131 T PT 3101131T
- Authority
- PT
- Portugal
- Prior art keywords
- transthyretin
- humanized antibody
- humanized
- antibody
- transthyretin humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014014911 | 2014-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3101131T true PT3101131T (pt) | 2020-11-05 |
Family
ID=53756905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157432303T PT3101131T (pt) | 2014-01-29 | 2015-01-23 | Anticorpo antitranstirretina humanizado |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10604562B2 (pt) |
| EP (1) | EP3101131B1 (pt) |
| JP (1) | JP6818268B2 (pt) |
| KR (1) | KR102538555B1 (pt) |
| CN (1) | CN106574258B (pt) |
| PT (1) | PT3101131T (pt) |
| WO (1) | WO2015115331A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60774B1 (sr) | 2013-12-20 | 2020-10-30 | Neurimmune Holding Ag | Lečenje transtiretinske (ttr) amiloidoze na bazi antitela i odgovarajuća antitela humanog porekla |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| AU2016297513B2 (en) * | 2015-07-17 | 2021-02-25 | Board Of Regents, The University Of Texas System | Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue |
| WO2019039332A1 (ja) * | 2017-08-23 | 2019-02-28 | 富士フイルム株式会社 | 金属箔、金属箔の製造方法、二次電池用負極および二次電池用正極 |
| ES2962277T3 (es) | 2017-09-29 | 2024-03-18 | Regeneron Pharma | Roedores que comprenden un locus Ttr humanizado y métodos de uso |
| EP3691626A4 (en) * | 2017-10-06 | 2021-06-30 | Prothena Biosciences Limited | METHODS OF DETECTION OF TRANSTHYRETINE |
| AU2018345806A1 (en) | 2017-10-06 | 2020-03-12 | Novo Nordisk A/S | Anti-transthyretin antibodies |
| BR112020010483A2 (pt) | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| CN112888455B (zh) | 2018-10-25 | 2024-12-24 | Km生物医薬股份公司 | 修饰CMVgB蛋白及包含其的CMV疫苗 |
| EP3801011A1 (en) | 2019-06-04 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| IL298135A (en) | 2020-05-12 | 2023-01-01 | Neurimmune Ag | Combination therapy for ttr amyloidosis |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| EP4630812A1 (en) | 2022-12-05 | 2025-10-15 | Neurimmune AG | Cyclic compounds and their use in assays for detecting antibodies |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2024251997A1 (en) | 2023-06-07 | 2024-12-12 | Neurimmune Ag | Vaccine for the treatment of amyloidosis |
| CN121487964A (zh) * | 2023-06-14 | 2026-02-06 | 艾慕特林有限公司 | 抗原纤维抗体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1405912B8 (en) | 2001-07-06 | 2012-10-24 | The Chemo-Sero-Therapeutic Research Institute | Genetically modified ecarin and process for producing the same |
| US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
| US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| ES2603061T3 (es) | 2007-10-25 | 2017-02-23 | The Scripps Research Institute | Interrupción de la percepción de quórum en bacterias mediada por anticuerpos |
| EA028356B1 (ru) | 2007-12-28 | 2017-11-30 | Протена Байосайенсиз Лимитед | Лечение и профилактика амилоидоза |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| JP2010195710A (ja) * | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| PE20150091A1 (es) * | 2012-02-24 | 2015-02-16 | Stem Centrx Inc | Anticuerpos anti-sez6 y metodos de empleo |
| US9534048B2 (en) | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| US9790269B2 (en) * | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
-
2015
- 2015-01-23 JP JP2015559912A patent/JP6818268B2/ja active Active
- 2015-01-23 US US15/114,600 patent/US10604562B2/en active Active
- 2015-01-23 CN CN201580017195.3A patent/CN106574258B/zh active Active
- 2015-01-23 WO PCT/JP2015/051856 patent/WO2015115331A1/ja not_active Ceased
- 2015-01-23 KR KR1020167023087A patent/KR102538555B1/ko active Active
- 2015-01-23 PT PT157432303T patent/PT3101131T/pt unknown
- 2015-01-23 EP EP15743230.3A patent/EP3101131B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015115331A1 (ja) | 2015-08-06 |
| CN106574258A (zh) | 2017-04-19 |
| KR20160113206A (ko) | 2016-09-28 |
| JPWO2015115331A1 (ja) | 2017-03-23 |
| EP3101131A4 (en) | 2017-06-28 |
| CN106574258B (zh) | 2021-03-30 |
| JP6818268B2 (ja) | 2021-01-20 |
| KR102538555B1 (ko) | 2023-05-30 |
| US10604562B2 (en) | 2020-03-31 |
| EP3101131B1 (en) | 2020-08-19 |
| US20160347832A1 (en) | 2016-12-01 |
| EP3101131A1 (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288649A (en) | Human antibodies against tau | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| IL252004A0 (en) | Ether-substituted antibody | |
| IL250415A0 (en) | Antibodies against pd-l1 | |
| PT3101131T (pt) | Anticorpo antitranstirretina humanizado | |
| IL256579A (en) | Human antibodies | |
| IL248402A0 (en) | Humanized antibodies against ceacam1 | |
| IL247371A0 (en) | Antibodies from individuals with increased stability | |
| GB201410520D0 (en) | Antibody | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| IL248220A0 (en) | Anti- nme antibody | |
| IL250404A0 (en) | A new anti-igbeta antibody of human origin | |
| SG11201700922YA (en) | Anti-orai1 antibody | |
| PL3112463T3 (pl) | Nowe przeciwciało przeciwko presepsynie | |
| PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
| GB201418781D0 (en) | Antibody epitope | |
| GB201418776D0 (en) | Antibody | |
| GB201413745D0 (en) | Antibody | |
| GB201411319D0 (en) | Antibody | |
| GB201407535D0 (en) | Antibody Drug - Conjugates |